EFTA02572130.pdf

From: jeffrey E. <[email protected]> Sent: Friday, November 3, 2017 9:25 AM To: Masha Drokova Subject: Re: intrested in mony =br> On Fri, Nov 3, 2017 at 3:18 AM, Masha Drokov= wrote: what is investor type btw? =hat is one main quality for investor? <=iv>On Nov 2, 2017, at 9:53 PM, jeffrey E. <[email protected] <mailto:[email protected]» wrote: =/div> He is not an in=estor type . He is s partner at a firm but used to be at Microsoft. =ust use him for advice 11:13 PM Masha Drokova wrote: Thank you for=the comprehensive feedback Steven. For me the main value is that the system is a= order of magnitude cheaper than existing technologies, premised on levera=ing data to help users see what daily elements are affecting their blood s=gar, and predicting dangerous highs and lows before they happen so they ca= take actions beforehand. To date, their beta app has lowered blood sugar averages i= over 55% of users 2x better than the world's most prescribed diabetes=drug, Metformin. Which means that with the help of the date diabetes would=need to use less drugs. However I'd agree on complexity of regulations and satur=tion on the market. I run Day One Ve=tures fund and based in San Francisco. I'd be happy to connect in pers=n sometime to learn about about your experience and tell about our investm=nts and opportunities I see. O= Nov 2, 2017, at 3:24 PM, Steven Sinofsky wrote: Greetings Masha, I apologize for the delay. I was at some events in in=UK where I did not have connectivity. EFTA_R1_01741593 EFTA02572130  I have work=d on a related portfolio company so I will have to be a bit abstract on th= specifics of this opportunity. So please excuse these brief thought=. Also, the only information I had was what was provided in your mail whic= was limited relative to any detailed analysis. *=In general the challenge with glucose measurement is the finger prick. Any=device that relies on this will only be marginally better than any other d=vice, whether or not there is software or a slightly more convenient measu=ing device. This is a statement about the inconvenience of a prick (and lo=g term challenges) but also the medical challenges on relying on that poin= in time. * My sense is that going down the path of an innovatio=, that still has a prick, but requires a level of FDA approval is a diffic=lt one to approach. • This is a very crowded space. There are a =ot of apps, a lot of measuring devices, a lot of mixtures of app and measu=ing devices. It is very difficult to avoid appearing as a commodity to con=umers. * While I understand there is potential to see innovation=using novel approaches to analysis of data, it is not clear to me how much=better the approach can be for an individual with data. • The re=l opportunity I might see is around measuring glucose or some related tele=etry to assist in compliance that is outside the scope of a finger prick a=d measuring glucose directly. It seems like we should have some other data=point upon which to apply machine learning. I hop= this helps...any friend of JE is a friend of mine. On Nov 1= 2017, at 4:43 PM, Masha Drokova > wrote: <=lockquote type="cite"> Thank you Jeffrey. Steve, gre=t meeting you. Would appreciate your feedback <=iv> On Nov 1, 2017, at 9:31 AM, jeffrey E. <[email protected] <mailto:jeevac=tion@gmailcom» wrote: =br> steve can you give some guida=ce =d, Nov 1, 2017 at 12:20 PM, Masha Drokova . .n If >=wrote: I'm looking to in=est at the company doing AI-based glucose monitoring system for people wit= diabetes. We made tech evaluation, talked to a few experts and more=a question about the market and regulations. Likely no, because it&#=9;s complex area, but still thinking of them. May be someone in your netw=rk who knows this area and can advise on this kind of tech? </=iv> Center Health Deck: 2 EFTA_R1_01741594 EFTA02572131  Our memo: https://docs.google.com/document/d/1M7ZV7VEI8CTnb4EtYWFH2sq5=cCm0PM6g1AlcwrIOtM <https://docs.google=com/document/d/1M72V7VEI8anb4EtYWFH2sq5dcCm0PM6g1AlcwrIOtM> <=ont face="Roboto-Regular"> Center Health is=C2*building an Al-based glucose monitoring system for the 1 in 11A=ericans who suffer from diabetes, based on machine learning and their pers=nalized Al, Aria. Users subscribe to their disposable test strips, a =14B/yr US market, which are delivered monthly, as Aria learns about their =iabetes and prompts behavioral changes to lower blood sugar. The=system is an order of magnitude cheaper than existing technologies, premis=d on leveraging data to help users see what daily elements are affect=ng their blood sugar, and predicting dangerous highs and lows before they =appen. Pros — Exist=ng glucometers from big companies are very old-fashioned and outdated, tho=e companies make their revenue from overpriced strips <=iv style="font-weight:normal">40=94 Direct competitors, such as iHealth and Dario have negative=customer reviews and minor <=ont face="Roboto-Regular">— Uses FDA-approved circuits to g=t the approval in an automated manner =ons — Enormous pressure both from the industry p=ayers and companies such as Apple and Google that try to develop non-invas=ve glucose monitoring that will wipe out test strip products=/div> — Young team p=ease note The information contained in this communication is co=fidential, may be attorney-client privileged, may constitute inside inf=rmation, and is intended only for the use of the addressee. It is the p=operty of JEE Unauthorized use, disclosure or copying of this com=unication or any part thereof is strictly prohibited and may be unlawfu.. If you have received this communication in error, please notify us im=ediately by return e-mail or by e-mail to [email protected] <mailto:jeevacation=gmail.com> , and destroy thi= communication and all copies thereof, including all attachments. copyr=ght -all rights reserved =C24, please note 3 EFTA_R1_01741595 EFTA02572132  The informat=on contained in this communication is confidential, may be attorney-cli=nt privileged, may constitute inside information, and is intended only =or the use of the addressee. It is the property of JEE Unauthoriz=d use, disclosure or copying of this communication or any part thereof =s strictly prohibited and may be unlawful. If you have received this return e-mail o= by e-mail to [email protected] <mailto:[email protected]> , and destroy this communication and all copies =hereof, including all attachments. copyright -all rights reserved </=iv> please note Th= information contained in this communication is confidential, may be at=orney-client privileged, may constitute inside information, and is inte=ded only for the use of the addressee. It is the property of JEE =nauthorized use, disclosure or copying of this communication or any par= thereof is strictly prohibited and may be unlawful. If you have receiv=d this communication in error, please notify us immediately by retur= e-mail or by e-mail to conversation-id 25269 date-last-viewed 0 date-received 1509701111 flags 8590195713 gmail-label-ids 7 remote-id 764759 <mailto:[email protected]> 4 EFTA_R1_01741596 EFTA02572133